The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1336
Edluar - A New Sublingual Formulation of Zolpidem
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Edluar - A New Sublingual Formulation of Zolpidem
Edluar (Meda), a new sublingual tablet formulation of the benzodiazepine receptor agonist zolpidem (Ambien, and others), has been approved by the FDA for treatment of insomnia.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Edluar - A New Sublingual Formulation of Zolpidem
Article code: 1336b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.